A plea for appraisal and appreciation of immunohistochemistry in the assessment of prognostic and predictive markers in invasive breast cancer

被引：16

作者：

Van Bockstal, Mieke ^{[1
,2
]}

Floris, Giuseppe ^{[3
,4
]}

Galant, Christine ^{[5
]}

Lambein, Kathleen ^{[6
,7
]}

Libbrecht, Louis ^{[5
]}

机构：

[1] Ghent Univ Hosp, Dept Pathol, De Pintelaan 185, B-9000 Ghent, Belgium

[2] Univ Ghent, Dept Med & Forens Pathol, CRIG, Ghent, Belgium

[3] Univ Leuven, Dept Imaging & Pathol, Lab Translat Cell & Tissue Res, Leuven, Belgium

[4] Univ Hosp Leuven, Dept Pathol, Leuven, Belgium

[5] Univ Clin St Luc, Dept Pathol, Hippokrateslaan 10, B-1200 Sint Lambrechts Woluwe, Belgium

[6] AZ St Lucas Hosp, Dept Pathol, Groenebriel 1, B-9000 Ghent, Belgium

[7] Katholieke Univ Leuven, Dept Oncol, Surg Oncol, Univ Hosp Leuven, Herestr 49, B-3000 Leuven, Belgium

来源：

BREAST | 2018年 / 37卷

关键词：

Immunohistochemistry; Genomic testing; Breast cancer; HER2; Hormone receptor status; RT-qPCR; RNA; CARCINOMA IN-SITU; AMERICAN PATHOLOGISTS GUIDELINE; INTERNATIONAL EXPERT CONSENSUS; HER2 AMPLIFICATION STATUS; ONCOTYPE DX TEST; CLINICAL ONCOLOGY/COLLEGE; ESTROGEN-RECEPTOR; RECURRENCE RISK; PRIMARY THERAPY; EXPRESSION;

D O I：

10.1016/j.breast.2017.10.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This viewpoint is a personal reflection on the values and merits of immunohistochemistry in current breast cancer diagnosis. Immunohistochemistry is a validated mainstay in molecular subtyping of invasive breast cancer. Immunohistochemical assessment of hormone receptor status and HER2 expression is used to determine the clinico-pathological surrogate of breast cancer intrinsic subtypes, which guide neoadjuvant and adjuvant therapy. The advent of genomic prognostic signatures and qualitative mRNA-based assays makes some clinicians and researchers wonder whether immunohistochemistry should be abandoned. However, the perils and pitfalls of these mRNA-based tests cannot be neglected. This viewpoint offers a brief overview of quality issues in immunohistochemistry and qPCR, as well as a concise summary of currently available evidence on the correlation of immunohistochemistry and mRNA-based testing for prognostic and predictive markers in invasive breast cancer. We strongly advocate the use of immunohistochemistry as it integrates valuable spatial information with quantification of protein expression. (c) 2017 Elsevier Ltd. All rights reserved.

引用

页码：52 / 55

页数：4

共 37 条

[1] A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas [J].

Acs, Geza ;

Esposito, Nicole N. ;

Kiluk, John ;

Loftus, Loretta ;

Laronga, Christine .

MODERN PATHOLOGY, 2012, 25 (04) :556-566

[2] A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer [J].

Alvarado, Michael D. ;

Prasad, Che ;

Rothney, Megan ;

Cherbavaz, Diana B. ;

Sing, Amy P. ;

Baehner, Frederick L. ;

Svedman, Christer ;

Markopoulos, Christos J. .

ADVANCES IN THERAPY, 2015, 32 (12) :1237-1247

[3] Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others [J].

Bartlett, John M. S. ;

Bayani, Jane ;

Marshall, Andrea ;

Dunn, Janet A. ;

Campbell, Amy ;

Cunningham, Carrie ;

Sobol, Monika S. ;

Hall, Peter S. ;

Poole, Christopher J. ;

Cameron, David A. ;

Earl, Helena M. ;

Rea, Daniel W. ;

Macpherson, Iain R. ;

Canney, Peter ;

Francis, Adele ;

McCabe, Christopher ;

Pinder, Sarah E. ;

Hughes-Davies, Luke ;

Makris, Andreas ;

Stein, Robert C. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2016, 108 (09)

[4] HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable [J].

Beltjens, F. ;

Bertaut, A. ;

Pigeonnat, S. ;

Loustalot, C. ;

Desmoulins, I. ;

Charon-Barra, C. ;

Coudert, B. ;

Fumoleau, P. ;

Arveux, P. ;

Arnould, L. .

EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (02)

[5] Oncotype DX Test on Unequivocally HER2-Positive Cases: Potential for Harm [J].

Bhargava, Rohit ;

Dabbs, David J. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) :570-571

[6] An Audit of Failed Immunohistochemical Slides in a Clinical Laboratory: The Role of On-Slide Controls [J].

Cheung, Carol C. ;

Taylor, Clive R. ;

Torlakovic, Emina E. .

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2017, 25 (05) :308-312

[7] Recognition and Handling of Discordant Negative Human Epidermal Growth Factor Receptor 2 Classification by Oncotype DX in Patients With Breast Cancer [J].

Christgen, Matthias ;

Harbeck, Nadia ;

Gluz, Oleg ;

Nitz, Ulrike ;

Kreipe, Hans H. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) :3313-3314

[8] Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [J].

Coates, A. S. ;

Winer, E. P. ;

Goldhirsch, A. ;

Gelber, R. D. ;

Gnant, M. ;

Piccart-Gebhart, M. ;

Thuerlimann, B. ;

Senn, H. -J. .

ANNALS OF ONCOLOGY, 2015, 26 (08) :1533-1546

[9] De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 [J].

Curigliano, G. ;

Burstein, H. J. ;

Winer, E. P. ;

Gnant, M. ;

Dubsky, P. ;

Loibl, S. ;

Colleoni, M. ;

Regan, M. M. ;

Piccart-Gebhart, M. ;

Senn, H. -J. ;

Thurlimann, B. ;

Andre, F. ;

Baselga, J. ;

Bergh, J. ;

Bonnefoi, H. ;

Brucker, S. Y. ;

Cardoso, F. ;

Carey, L. ;

Ciruelos, E. ;

Cuzick, J. ;

Denkert, C. ;

Di Leo, A. ;

Ejlertsen, B. ;

Francis, P. ;

Galimberti, V. ;

Garber, J. ;

Gulluoglu, B. ;

Goodwin, P. ;

Harbeck, N. ;

Hayes, D. F. ;

Huang, C. -S. ;

Huober, J. ;

Khaled, H. ;

Jassem, J. ;

Jiang, Z. ;

Karlsson, P. ;

Morrow, M. ;

Orecchia, R. ;

Osborne, K. C. ;

Pagani, O. ;

Partridge, A. H. ;

Pritchard, K. ;

Ro, J. ;

Rutgers, E. J. T. ;

Sedlmayer, F. ;

Semiglazov, V. ;

Shao, Z. ;

Smith, I. ;

Toi, M. ;

Tutt, A. .

ANNALS OF ONCOLOGY, 2017, 28 (08) :1700-1712

[10] High False- Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study [J].

Dabbs, David J. ;

Klein, Molly E. ;

Mohsin, Syed K. ;

Tubbs, Raymond R. ;

Shuai, Yongli ;

Bhargava, Rohit .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) :4279-4285

← 1 2 3 4 →